Kadcyla Wins US FDA Approval for Late-Stage Breast Cancer

Ado-trastuzumab emtansine, a HER-2 targeted antibody-drug conjugate, has been approved by the U.S. Food and Drug Administration for treatment of women with HER2-positive, late-stage metastatic breast cancer,...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news